Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells

被引:49
作者
Li, Yan [1 ]
Backesjo, Carl-Magnus [1 ]
Haldosen, Lars-Arne [2 ]
Lindgren, Urban [1 ]
机构
[1] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Orthoped, S-14186 Huddinge, Sweden
[2] Karolinska Inst, Dept Biosci & Nutr, S-14186 Huddinge, Sweden
关键词
Sirt1; Osteosarcoma; Resveratrol; Isonicotinamide; L-asparaginase; CALORIE RESTRICTION; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; NICOTINAMIDE INHIBITION; SIRT1; DEACETYLASE; L-ASPARAGINASE; CANCER; LONGEVITY; CHEMOTHERAPY; RESISTANCE;
D O I
10.1016/j.ejphar.2009.03.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The phytoalexin resveratrol has been described to have chemopreventive and chemotherapeutic effects in several tumor models while its effects on osteosarcoma have not been extensively studied. Additionally, resveratrol is a potent activator of the Sirt1/Sir2 (silent information regulator 2) family of NAD-dependent deacetylases which plays a role in calorie restriction-mediated tumor suppression. In the present study, we evaluated the effect of resveratrol on growth and apoptosis in four osteosarcoma cell lines (HOS, Saos-2, U-2 OS and MG-63) and a normal human osteoblast cell line (NHOst). We found that Sirt1 protein was relatively higher expressed in the tumor cells than normal osteoblasts. Consistently, resveratrol induced apoptosis in a dose-dependent fashion in the osteosarcoma cells but had minor effect on normal osteoblasts. Also, a similar effect could be elicited by another Sirt1 activator, isonicotinamide. In addition, the pro-apoptotic effect of resveratrol could be enhanced by nutrition restriction elicited by L-asparaginase. We postulate that these effects by resveratrol are mediated via Sirt1 but further studies are needed to confirm or refute this theory. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 45 条
  • [1] Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae
    Anderson, RM
    Bitterman, KJ
    Wood, JG
    Medvedik, O
    Sinclair, DA
    [J]. NATURE, 2003, 423 (6936) : 181 - 185
  • [2] Resveratrol: A review of preclinical studies for human cancer prevention
    Athar, Mohammad
    Back, Jung Ho
    Tang, Xmwel
    Kim, Kwang Ho
    Kopelovich, Levy
    Bickers, David R.
    Kim, Arianna L.
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 224 (03) : 274 - 283
  • [3] Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report
    Bacci, G
    Ferrari, S
    Bertoni, F
    Ruggieri, P
    Picci, P
    Longhi, A
    Casadei, R
    Fabbri, N
    Forni, C
    Versari, M
    Campanacci, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) : 4016 - 4027
  • [4] Bavaresco L, 2003, DRUG EXP CLIN RES, V29, P181
  • [5] Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1
    Bitterman, KJ
    Anderson, RM
    Cohen, HY
    Latorre-Esteves, M
    Sinclair, DA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (47) : 45099 - 45107
  • [6] Calorie restriction, SIRT1 and metabolism: Understanding longevity
    Bordone, L
    Guarente, L
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (04) : 298 - 305
  • [7] Bradamante S, 2004, CARDIOVASC DRUG REV, V22, P169
  • [8] Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1
    Chu, F
    Chou, PM
    Zheng, X
    Mirkin, BL
    Rebbaa, A
    [J]. CANCER RESEARCH, 2005, 65 (22) : 10183 - 10187
  • [9] Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
    Cohen, HY
    Miller, C
    Bitterman, KJ
    Wall, NR
    Hekking, B
    Kessler, B
    Howitz, KT
    Gorospe, M
    de Cabo, R
    Sinclair, DA
    [J]. SCIENCE, 2004, 305 (5682) : 390 - 392
  • [10] Resveratrol as a chemopreventive agent:: A promising molecule for fighting cancer
    Delmas, D
    Lançon, A
    Colin, D
    Jannin, B
    Latruffe, N
    [J]. CURRENT DRUG TARGETS, 2006, 7 (04) : 423 - 442